OKYO Pharma (OKYO) CFO receives grant of 40,000 options at $1.85

Rhea-AI Filing Summary

OKYO Pharma Ltd reported that Chief Financial Officer Keeren Rameshchandra Shah received a grant of options covering 40,000 common shares at an exercise price of $1.85 per share. These options are exercisable beginning on June 8, 2027 and expire on June 8, 2036. Following this award, the filing shows 544,819 derivative securities held directly, indicating this is a compensation-related grant rather than an open-market purchase.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Shah Keeren Rameshchandra

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Option	40,000	$1.85	$74K

Holdings After Transaction: Option — 544,819 shares (Direct, null)

Footnotes (1)

Key Figures

Option grant size: 40,000 options Exercise price: $1.85 per share Underlying common shares: 40,000 shares +3 more

6 metrics

Option grant size 40,000 options Grant to CFO on June 8, 2026

Exercise price $1.85 per share Strike price for granted options

Underlying common shares 40,000 shares Shares deliverable upon option exercise

Total derivatives after grant 544,819 securities Derivative securities held directly after transaction

Exercise start date June 8, 2027 First exercisable date for the options

Expiration date June 8, 2036 Final expiration of the option award

Key Terms

Grant, award, or other acquisition, Option, Common Shares, exercise price

4 terms

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

Option financial

"security_title: Option with underlying common shares"

Common Shares financial

"underlying_security_title: Common Shares"

Common shares are the basic units of ownership in a company that give holders a claim on profits and a right to vote on key matters, like electing the board. Think of them as membership cards in a club: they let you share in successes and losses, but in a bankruptcy or liquidation they are paid after creditors and preferred shareholders, so their value can swing more and matters for assessing risk and potential return.

exercise price financial

"conversion_or_exercise_price of 1.8500 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Shah Keeren Rameshchandra

(Last) (First) (Middle)

14-15 CONDUIT ST

(Street)

LONDON W1S 2XJ

(City) (State) (Zip)

UNITED KINGDOM

(Country)

2. Issuer Name and Ticker or Trading Symbol
OKYO Pharma Ltd [ OKYO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option	$1.85	06/08/2026	06/08/2026	A		40,000		06/08/2027	06/08/2036	Common Shares	40,000	$1.85	544,819	D

Explanation of Responses:

Remarks:

Options vest 25% per year over four years beginning on the first anniversary of the grant date

	/s/ Keeren Shah	06/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did OKYO Pharma (OKYO) report for its CFO?

OKYO Pharma reported its CFO received a grant of options on 40,000 common shares. The award is a compensation-related grant, not an open-market share purchase, and was disclosed as a derivative transaction in the latest insider report.

At what price were the new OKYO Pharma (OKYO) CFO options granted?

The CFO’s new options were granted with an exercise price of $1.85 per share. This means the holder can buy common shares at $1.85 once exercisable, regardless of the market price at that future time.

When can the OKYO Pharma (OKYO) CFO begin exercising the new options?

The options become exercisable on June 8, 2027. From that date until expiration, the CFO may choose to convert the options into common shares at the stated exercise price, subject to any additional plan terms not shown here.

When do the newly granted OKYO Pharma (OKYO) CFO options expire?

The options granted to the CFO expire on June 8, 2036. After this expiration date, any unexercised options become worthless, so potential value from this award depends on both share price performance and timely exercise.

How many derivative securities does the OKYO Pharma (OKYO) CFO hold after this grant?

After the 40,000-option grant, total derivative securities reported as held directly are 544,819. This figure shows the CFO’s overall option-based exposure to OKYO Pharma’s common shares following the latest compensation-related award.

Was the OKYO Pharma (OKYO) CFO’s transaction a market buy or a compensation grant?

The transaction was a compensation-related grant, described as a “Grant, award, or other acquisition.” It did not involve an open-market share purchase or sale, but rather an option award giving future rights to acquire common shares.